Interferon therapy in rheumatic diseases: State-of-the-art 2010

Current Opinion in Rheumatology

Volumn 22, Issue 3, 2010, Pages 278-283

  Kötter, Ina ^a   Hamuryudan, Vedat ^b   A Ztürk, Zafer E ^c   Yazici, Hasan ^b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b ISTANBUL UNIVERSITY   (Turkey)

^c MEDIMMUNE   (United States)

Author keywords

Beh et's disease; Cryoglobulinemia; Familial Mediterranean fever; Interferon; Uveitis; Vasculitis

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; AZATHIOPRINE; COLCHICINE; INTERFERON; PEGINTERFERON ALPHA; PREDNISOLONE; RIBAVIRIN; RITUXIMAB;

ALOPECIA; ANTIBODY PRODUCTION; ARTHRALGIA; AUTOIMMUNE DISEASE; BEHCET DISEASE; BONE MARROW SUPPRESSION; CHURG STRAUSS SYNDROME; CRYOGLOBULINEMIA; DEPRESSION; DRUG DOSE TITRATION; FAMILIAL MEDITERRANEAN FEVER; FEVER; FIBROMYALGIA; FLU LIKE SYNDROME; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE ERYTHEMA; LEUKOPENIA; MONONEUROPATHY; OPTIC NERVE DISEASE; POLYNEUROPATHY; PRIORITY JOURNAL; PSORIASIS; REMISSION; RETINA DISEASE; RETINA VASCULITIS; RETINOPATHY; REVIEW; RHEUMATIC DISEASE; SIDE EFFECT; THYROIDITIS; TREATMENT INDICATION; VISUAL ACUITY; WEIGHT REDUCTION;

ANTIRHEUMATIC AGENTS; BEHCET SYNDROME; CRYOGLOBULINEMIA; DRUG THERAPY, COMBINATION; DRUG TOXICITY; FAMILIAL MEDITERRANEAN FEVER; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; RHEUMATIC DISEASES;

EID: 77950212921     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3283368099     Document Type: Review

References (65)

1. Meyer O. Interferons and autoimmune disorders. Joint Bone Spine 2009;76:464-473.
2. Baum A, Garćia-Sastre A. Induction of type I interferon by RNA viruses: cellular receptors and their substrates. Amino Acids 2009 Nov 1. [Epub ahead of print]
3. Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (alpha/ beta) in immunity and autoimmunity. Annu Rev Immunol 2005; 23:307-336.
4. Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009; 8:987-997.
5. O'Connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg interferon beta-1b versus 20mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009; 8:889-897.
6. Safdar A, Rodriguez G, Ohmagari N, et al. The safety of interferon-gamma-1b therapy for invasive fungal infections after hematopoietic stem cell transplantation. Cancer 2005; 103:731-739.
7. Li Q, Kawamura K, Ma G, et al. Interferon-lambda induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces antitumour effects in combination with anticancer agents. Eur J Cancer 2010; 46:180-190.
8. Borg FAY, Isenberg DA. Syndromes and complications of interferon therapy. Curr Opin Rheumatol 2007; 19:61-66.
9. Venezia G, Licata A, Di Marco V, et al. Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b. Dig Liver Dis 2005; 37:882-885.
10. Banchereau J, Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006; 25:383-392.
11. Dall'era MC, Cardarelli PM, Preston BT, et al. Type I interferon correlates with clinical and serologic manifestations of systemic lupus erythematosus. Ann Rheum Dis 2005; 64:1692-1697.
12. Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005; 57:664-678.
13. O'Connor KA, Abbott KA, Sabin B, et al. MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement. Clin Immunol 2006; 120:319-325.
14. Yao Y, Richman L, Higgs BW, et al. Neutralization of interferon-alpha/ beta-inducible genes and downstream effect in a phase I trial of an antiinterferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009; 60:1785-1796.
15. Tsambaos D, Eichelberg D, Goos M. Behcet's syndrome: treatment with recombinant leukocyte alpha-interferon. Arch Dermatol Res 1986; 278:335-336.
16. Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 2002; 138:467-471.
17. Hamuryudan V, Ozyazgan Y, Fresko Y, et al. Interferon alfa combined with azathioprineforthe uveitis of Behcet's disease: an open study. Isr Med Assoc J 2002; 4:928-930.
18. Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behcet disease. Ann Rheum Dis 2008; 67:1656-1662.
19. Kotter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003; 87:423-431.
20. Kotter I, Gunaydin I, Zierhut M, Stubiger N. The use of interferon alpha in Behcet disease: review of the literature. Semin Arthritis Rheum 2004; 33:320-335.
21. Kotter I, Vonthein R, Zierhut M, et al. Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behcet disease: results of an open 4-center trial. Semin Arthritis Rheum 2004; 33:311-319.
22. DeuterCM, Kotter I, Gunaydin I, et al. Ocular involvement in Behcet's disease: first 5-year-results for visual development after treatment with interferon alfa-2a. Ophthalmologe 2004; 101:129-134.
23. Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M. Results of interferon-alfa therapy in patients with Behcet uveitis. Graefes Arch Clin Exp Ophthalmol 2006; 244:1692-1695.
24. Gueudry J, Wechsler B, TerradaC, et al. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behcet disease. Am J Ophthalmol 2008; 146:837-844.
25. Krause L, Altenburg A, Pleyer U, et al. Longterm visual prognosis of patients with ocular Adamantiades-Behcet's disease treated with interferon-alpha-2a. J Rheumatol 2008; 35:896-903.
26. Krause L, Kohler AK, Altenburg A, et al. Ocular involvement in Adamantiades-Behcet's disease in Berlin, Germany. Graefes Arch Clin Exp Ophthalmol 2009; 247:661-666.
27. Deuter C, Kotter I, Mohle A, et al. Long-term observations of vision and relapse-free intervals in patients with severe uveitis due to Behcet's disease treated with interferon alfa [abstract #2694]. ARVO 2009.
28. Deuter CM, Kotter I, Wallace GR, et al. Behcet's disease: ocular effects and treatment. Prog Retin Eye Res 2008; 27:111-136.
29. Guillaume-Czitrom S, Berger C, Pajot C, et al. Efficacy and safety of inter-feron-alpha in the treatment of corticodependent uveitis of paediatric Behcet's disease. Rheumatology (Oxford) 2007; 46:1570-1573.
30. Kuemmerle-Deschner JB, Tzaribachev N, Deuter C, et al. Interferon-alpha-a new therapeutic option in refractory juvenile Behcet's disease with CNS involvement. Rheumatology (Oxford) 2008; 47:1051-1053.
31. Hamuryudan V, Yurdakul S, Rosenkaimer F, Yazici H. Inefficacy of topical alpha interferon in the treatment of oral ulcers of Behcet's syndrome: a randomized, double blind trial. Br J Rheumatol 1991; 30:395-396.
32. Kilic H, Zeytin HE, Korkmaz C, et al. Low-dose natural human interferon-alpha lozenges in the treatment of Behcet's syndrome. Rheumatology (Oxford) 2009; 48:1388-1391.
33. Aderka D, Pras M, Bino T, et al. Absence of interferon activity during acute attacks of familial Mediterranean fever. Biomedicine 1980; 33:95-96.
34. Tankurt E, Tunca M, Akbaylar H, Gonen O. Resolving familial Mediterranean fever attacks with interferon alfa. Br J Rheumatol 1996; 35:1188-1189.
35. Tunca M, Tankurt E, Akbaylar H, et al. The efficacy of interferon alpha on colchicine resistant familial mediterranean fever attacks: a pilot study. Br J Rheumatol 1997; 36:1005-1008.
36. Tunca M, Akar S, SoyturkM, et al. The effect of interferon alpha administration on acute attacks of familial Mediterranean fever: a double-blind, placebo-controlled trial. Clin Exp Rheumatol 2004; 22 (Suppl 34):S37-S40.
37. Calguneri M, AprasS, Ozbalkan Z, et al. The efficacy of continuous interferon alpha administration as an adjunctive agent to colchicine resistant familial Mediterranean fever patients. Clin Exp Rheumatol 2004; 22 (Suppl 34):S41-S44.
38. Tweezer-Zaks N, Rabinovich E, Lidar M, Livneh A. Interferon-alpha as a treatment modality for colchicine-resistant familial Mediterranean fever. J Rheumatol 2008; 35:1362-1365.
39. Oz GS, Emri S, Apras-Bilgen S. Development of interferon induced sarcoidosis in a patient with familial Mediterranean fever. Tuberk Toraks 2008; 56:319-324.
40. Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment virus C. Arthritis Rheum 1999; 42:2204-2212.
41. Ferri C. Mixed cryoglobulinemia. Orphanet J Rare Dis 2008; 3:25.
42. Bonomo L, Casato M, Afeltra A, Caccavo D. Treatment of idiopathic mixed cryoglobulinemia with alpha interferon. Am J Med 1987; 83:726-730.
43. Cacoub P, Saadoun D, Sene D, et al. Treatment of hepatitis c virus related systemic vasculitis. J Rheumatol 2005; 32:2078-2082.
44. Cacoub P, Saadoun D, Limal N, et al. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 2005; 52:911-915.
45. Saadoun D, Resche-Rigon M,Thibault V, et al. Antiviral therapy for hepatitis C virus associated mixed cryoglobulinemia vasculitis: a long term follow-up study. Arthritis Rheum 2006; 54:3696-3706.
46. Landau DA, Rosenzwajg M, Saadoun D, et al. Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis. Arthritis Rheum 2008; 58:2897-2907.
47. La Civita L, Zignego AL, Lombardini F, et al. Exacerbation of peripheral neuropathy during alpha-interferon therapy in a patient with mixed cryoglobulinemia and hepatitis B virus infection. J Rheumatol 1996; 23:1641-1643.
48. Cid MC, Hernandez-Rodriguez J, Robert J, et al. Interferon-alpha may exacerbate cryoblobulinemia-related ischemic manifestations: an adverse effect potentially related to its antiangiogenic activity. Arthritis Rheum 1999; 42:1051-1055.
49. Quartuccio L, Soardo G, Romano G, et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology (Oxford) 2006; 45:842-846.
50. Roccatello D, Baldovino S, Rossi D, et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004; 19:3054-3061.
51. Sansonno D, De Re V, Lauletta G, et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 2003; 101:3818-3826.
52. Saadoun D, Resche-Rigon M, Sene D, et al. Rituximab combined with Peg-interferon-ribavirin in refractory hepatis C virus-associated cryoglobulinemia vasculitis. Ann Rheum Dis 2008; 67:1431-1436.
53. Terrier B, Saadoun D, Sene D, et al. Efficacy and tolerability of rituximab with or without PEGylated interferon alpha-2b plus ribavirin in severe hepatitis C virus-related vasculitis. Arthritis Rheum 2009; 60:2531-2540.
54. Metzler C, Schnabel A, Gross WL, Hellmich B. A phase II study of interferon-alpha for the treatment of refractory Churg-Strauss syndrome. Clin Exp Rheumatol 2008; 26 (3 Suppl):S35-S40.
55. Canada R, Chaudry S, Gaber L, et al. Polyarteritis nodosa and cryoglobu-linemic glomerulonephritis related to chronic hepatitis C.Am J Med Sci 2006; 331:329-333.
56. Hauschild A, Kahler KC, Schafer M, Fluck M. Interdisciplinary management recommendations for toxicity associated with interferon-alfa therapy. J Dtsch Dermatol Ges 2008; 6:829-837; 829-838.
57. Wei YH, Wang IH, Woung LC, Jou JR. Anterior ischemic optic neuropathy associated with pegylated interferon therapy for chronic hepatitis C. Ocul Immunol Inflamm 2009; 17:191-194.
58. Post JW, Colleaux K. Interferon beta retinopathy in a patient with multiple sclerosis. Can J Ophthalmol 2009; 44:e37.
59. Sene D, Touitou V, Bodaghi B, et al. Intraocular complications of IFN-alpha and ribavirin therapy in patients with chronic viral hepatitis C. World J Gastroenterol 2007; 13:3137-3140.
60. Tomer Y, Blackard JT, Akeno N. Interferon alpha treatment and thyroid dysfunction. Endocrinol Metab Clin North Am 2007; 36:1051-1066; x-xi.
61. Burdick LM, Somani N, Somani AK. Type I IFNs and their role in the development of autoimmune diseases. Expert Opin Drug Saf 2009; 8:459-472.
62. Lotrich FE, Ferrell RE, Rabinovitz M, Pollock BG. Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorph ism. Biol Psychiatry 2009; 65:344-348.
63. Kraus MR, Schafer A, Schottker K, et al. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut 2008; 57:531-536.
64. Quelhas R, Lopes A. Psychiatric problems in patients infected with hepatitis C before and during antiviral treatment with interferon-alpha: a review. J Psy-chiatr Pract 2009; 15:262-281.
65. Myint AM, Schwarz MJ, Steinbusch HW, Leonard BE. Neuropsychiatric disorders related to interferon and interleukins treatment. Metab Brain Dis 2009; 24:55-68.